<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>G-protein-coupled receptor 40 (GPR40), known as free fatty acid receptor 1, is mainly expressed in pancreatic β-cells and activated by medium- and <z:chebi fb="0" ids="15904">long-chain fatty acids</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Increasing evidence indicates that the activation of GPR40 in cells causes insulin secretion, and GPR40 has become an attractive therapeutic target for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Recently, certain novel GPR40 <z:chebi fb="4" ids="48705">agonists</z:chebi> have been identified that regulate <z:chebi fb="105" ids="17234">glucose</z:chebi>-stimulated insulin secretion, leading to the development of new drugs for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In this review, we focus on progress in the physiological role of GPR40 and potential drugs targeting GPR40 over the past decade </plain></SENT>
</text></document>